Nilotinib Tasigna – New Treatment for Alzheimer's Alzheimer's disease is a brain disorder that destroys the nerve connections in the brain and further slowly destroys memory and thinking skills; makes difficult to do regular things like eating, and walking. • In short Alzheimer's can cause memory loss and can affect the cognitive abilities, this disease is not as normal as someone thinks and it mostly affects the people who are above 65 years. • Alzheimer's become worse with time. Dementia symptoms become worse gradually over the years. In the early stages, memory loss is mild, but with late-stage Alzheimer's, individuals face problem in having a conversation with others and face difficulties to cope with the environment. Alzheimer's in the USA is the 6th leading cause of death of an individual. • A person suffering from this disease has around 4-8 years of life expectancy after he has been diagnosed. Source: https://www.genuinedrugs123.com/Blog-154-NILOTINIB-TASIGNA%E2%80%93NEW-TREATMENT-FOR-ALZHEIMERS.aspx #Nilotinib #Tasigna #Alzheimers #NewTreatment #HopeForAlzheimers #AlzheimersResearch #BrainHealth #Neurology #Medication #Healthcare #AlzheimersAwareness #MedicalAdvancements #ClinicalTrials #Neuroscience #AlzheimersSupport #TreatmentOptions

The Effects of Gefitinib in EGFR Mutation Breast Cancer Researchers have explored this treatment concept that iressa / gefitinib in combination with fulvestrant (an estrogen receptor antagonist) can have a positive impact on the hormonal therapy's anti-tumour effect. Source: https://shorturl.at/bcsvH #Gefitinib #BreastCancer #CancerTreatment #TargetedTherapy #EGFRInhibitor #CancerResearch #Oncology #Healthcare #MedicalScience #SurvivorStories #BreastCancerAwareness #FightAgainstCancer #HopeForACure #TreatmentOptions #PrecisionMedicine #ChemotherapyAlternative #TherapeuticAdvancements #ClinicalTrials #SupportiveCare #Empowerment